Table 3.
Characteristics of Patients Colonized With Fluoroquinolone-Resistant Enterobacterales (FQRE) Who Did and Did Not Develop FQRE Bloodstream Infection
| Characteristic | FQRE BSI (n = 16) |
No FQRE BSI (n = 38) |
P Value |
|---|---|---|---|
| Demographics | |||
| Age, y, median (IQR) | 61 (50–65) | 61 (55–68) | .53 |
| Female sex | 7 (44) | 14 (37) | .63 |
| Race/ethnicity | |||
| White | 13 (81) | 29 (76) | .69 |
| Black | 3 (19) | 6 (16) | 1.00 |
| Asian | 0 | 3 (8) | .66 |
| Hispanic | 2 (13) | 4 (11) | 1.00 |
| Underlying malignancy | |||
| AML or MDS | 8 (50) | 9 (24) | .057 |
| ALL | 1 (6) | 4 (10) | 1.00 |
| Multiple myeloma | 1 (6) | 12 (32) | .079 |
| Non-Hodgkin lymphoma | 3 (19) | 10 (26) | .73 |
| Hodgkin lymphoma | 0 | 1 (3) | 1.00 |
| Other malignancy | 3 (19) | 2 (5) | .15 |
| ASBMT risk category [16] | |||
| Low risk | 9 (56) | 19 (50) | .68 |
| Medium risk | 1 (6) | 9 (24) | .25 |
| High risk | 4 (25) | 7 (18) | .71 |
| NA | 2 (13) | 3 (8) | .63 |
| Prior transplantation | |||
| Stem cell source | |||
| Autologous | 3 (19) | 21 (55) | .014 |
| Allogeneic | 13 (81) | 17 (45) | .014 |
| Matched related donor | 2 (13) | 5 (13) | 1.00 |
| Matched unrelated donor | 5 (31) | 5 (13) | .14 |
| Haploidentical-cord blood | 6 (38) | 6 (16) | .15 |
| Other | 0 | 1 (3) | 1.00 |
| Conditioning regimen | |||
| Fludarabine-melphalan-TBI | 8 (50) | 11 (29) | .14 |
| Melphalan | 0 | 10 (26) | .024 |
| Carmustine-etoposide-cytarabine-melphalan | 3 (19) | 7 (18) | 1.00 |
| Fludarabine-melphalan | 3 (19) | 3 (8) | .35 |
| Lenalidomide-melphalan | 0 | 2 (5) | 1.00 |
| Etoposide-TBI | 1 (6) | 1 (3) | .51 |
| Other regimen | 1 (6) | 4 (11) | 1.00 |
| Use of rituximab in conditioning | 8 (50) | 11 (29) | .14 |
| Anti–T-cell therapies for GVHD prophylaxis | |||
| Antithymocyte globulin | 5 (31) | 7 (18) | .31 |
| Alemtuzumab | 8 (50) | 8 (21) | .051 |
| Colonizing FQRE characteristics | |||
| Escherichia coli | 15 (94) | 34 (89) | 1.00 |
| ST131 | 8 (50) | 14 (38) | .41 |
| Levofloxacin MIC >32 µg/mL | 14 (88) | 35 (92) | .59 |
| ESBL producer | 4 (25) | 10 (26) | |
| Duration of neutropenia, d | 9 (9–11) | 8 (6–12) | .22 |
Data are presented as No. (%) unless otherwise indicated. Bolded P values indicate statistical significance.
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ASBMT, American Society of Bone Marrow Transplantation; BSI, bloodstream infection; ESBL, extended-spectrum β-lactamase; FQRE, fluoroquinolone-resistant Enterobacterales; GVHD, graft-vs-host disease; IQR, interquartile range; MDS, myelodysplastic syndrome; MIC, minimum inhibitory concentration; NA, not applicable; ST, sequence type; TBI, total body irradiation.